SYGNIS AG Installs Scalable Production Capability for Lightning-Link Antibody Conjugation Technology
January 16th, 2018
Heidelberg, Germany and Cambridge, UK, 16 January 2018: SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has extended the manufacturing capability for its Lightning-Link® technology, currently marketed under the Expedeon brand, to support scalability and bulk production of antibodies.
Lightning-Link is an innovative technology that enables direct labeling of antibodies or proteins in as little as 20 minutes, for use in R&D applications, drug discovery and the development of diagnostic kits. Lightning-Link kits are the world’s fastest, easiest to use and most efficient method of labeling antibodies or proteins, requiring only 30 seconds hands-on time, and there are no separation steps involved, meaning 100% of materials are retained.
The increased manufacturing capability means the Company is now able to offer the Lightning-Link product range in volumes from 10µg to 100mg, in single reaction vials tested with Rabbit IgG in ELISA. For antibody manufacturers that have fixed internal processes for conjugation, bulk supply of ultra-high quality raw materials and labels that are used in the Lightning-Link kits are also available.
Alastair Carrington, VP Business Development & Marketing, Expedeon, commented: “The ability to further support antibody manufacturers at both small and large scale, including those requiring bulk raw materials to work with historic standard operating procedures, provides the opportunity to reach new, high value markets. Access to Lightning-Link technology will enable manufacturers to dramatically increase their conjugate portfolios, whilst retaining batch-to-batch consistency.”
All raw materials used in Lightning-Link kits are manufactured from natural sources, grown in continuous microalgae culture, providing assurance of high quality purification with extreme quantum efficiency and excellent stability.
About SYGNIS AG: www.sygnis.com
SYGNIS develops and commercialises value-added, easy-to-use, reliable products for genomics and proteomics research based on its proprietary technologies, offering a wide range of solutions that address key challenges in molecular biology. With applications spanning the entire molecular biology workflow, the Group’s cutting-edge offerings include easy-to-use off-the-shelf products as well as custom services, supporting scientists from academia through to commercial manufacturing. SYGNIS’ products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. SYGNIS AG has offices in Germany, Spain, UK, USA and Singapore which trade under the Expedeon, Expedeon and C.B.S. Scientific brands. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).